For this, we used the L2 fully cross-species (human/mouse) reactive anti-ANTXR1 antibody (herein called T8Ab), previously developed for cancer therapy, which showed no toxicity after 6 weeks of dosing (20 mg kg−1, 3× per week)13. This evidence concerns the gene ANTXR1 and cancer.